Israel’s BioSight is pleased with its Phase I/IIa study to evaluate the safety and efficacy of its Astarabine treatment for Acute Myeloid Leukemia (AML) and relapsed/refractory Acute Lymphoblastic Leukemia (ALL). Full results later this year. (See also 1st Nov newsletter).
Good results in Leukemia treatment trials
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.